Antonarakis ES et al. A randomized phase 2 studyevaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data. Proc ASCO 2014;Abstract 5041.

de Bono JS et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364(21):1995-2005. Abstract

Fizazi K et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: Final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983-92. Abstract

Harland S et al. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer 2013;49(17):3648-57. Abstract

Kantoff PW et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22. Abstract

Schellhammer PF et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013;81(6):1297-302. Abstract

Scher HI et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187-97. Abstract

Trump DL et al. High-dose ketoconazole in advanced hormone-refractory prostate cancer: Endocrinologic and clinical effects. J Clin Oncol 1989;7(8):1093-8. Abstract